CO2018004576A2 - Composición farmacéutica que comprende ácidos grasos activados - Google Patents
Composición farmacéutica que comprende ácidos grasos activadosInfo
- Publication number
- CO2018004576A2 CO2018004576A2 CONC2018/0004576A CO2018004576A CO2018004576A2 CO 2018004576 A2 CO2018004576 A2 CO 2018004576A2 CO 2018004576 A CO2018004576 A CO 2018004576A CO 2018004576 A2 CO2018004576 A2 CO 2018004576A2
- Authority
- CO
- Colombia
- Prior art keywords
- fatty acids
- pharmaceutical composition
- activated fatty
- nitro
- methods
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 5
- 229930195729 fatty acid Natural products 0.000 title abstract 5
- 239000000194 fatty acid Substances 0.000 title abstract 5
- 150000004665 fatty acids Chemical class 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- -1 keto fatty acids Chemical class 0.000 abstract 2
- WRADPCFZZWXOTI-BMRADRMJSA-N (9E)-10-nitrooctadecenoic acid Chemical compound CCCCCCCC\C([N+]([O-])=O)=C/CCCCCCCC(O)=O WRADPCFZZWXOTI-BMRADRMJSA-N 0.000 abstract 1
- 229930194542 Keto Natural products 0.000 abstract 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000005206 focal segmental glomerulosclerosis Diseases 0.000 abstract 1
- 231100000854 focal segmental glomerulosclerosis Toxicity 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Varias modalidades de esta invención se dirigen a composiciones y métodos farmacéuticos para tratar enfermedades, incluyendo glomeruloesclerosis segmentaria focal o hipertensión arterial pulmonar. Las composiciones de tales modalidades incluyen ácidos grasos activados tales como ácidos grasos sustituidos con alquilo, ácidos grasos ceto y ácidos grasos nitro. Los métodos de varias modalidades incluyen administrar una cantidad efectiva de ácido 10-nitro-9(E)-octadec-9-enoico para tratar tales enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562236702P | 2015-10-02 | 2015-10-02 | |
PCT/US2016/055206 WO2017059451A1 (en) | 2015-10-02 | 2016-10-03 | Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018004576A2 true CO2018004576A2 (es) | 2018-07-19 |
Family
ID=58428002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0004576A CO2018004576A2 (es) | 2015-10-02 | 2018-04-27 | Composición farmacéutica que comprende ácidos grasos activados |
Country Status (17)
Country | Link |
---|---|
US (3) | US10537541B2 (es) |
EP (1) | EP3355879A4 (es) |
JP (2) | JP2018529779A (es) |
KR (1) | KR20180098222A (es) |
CN (2) | CN108430466A (es) |
AU (2) | AU2016331314A1 (es) |
BR (1) | BR112018006687A2 (es) |
CA (1) | CA3000842A1 (es) |
CL (1) | CL2018000835A1 (es) |
CO (1) | CO2018004576A2 (es) |
CR (1) | CR20180246A (es) |
EA (1) | EA201890859A1 (es) |
HK (1) | HK1259031A1 (es) |
IL (2) | IL258476B2 (es) |
MX (1) | MX2018004043A (es) |
SG (1) | SG10201913953UA (es) |
WO (1) | WO2017059451A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009134383A2 (en) * | 2008-05-01 | 2009-11-05 | Complexa Inc. | Vinyl substituted fatty acids |
US20140024713A1 (en) | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
ES2971969T3 (es) | 2015-07-07 | 2024-06-10 | H Lundbeck As | Inhibidores de PDE9 con cadena principal de imidazopirazinona para el tratamiento de enfermedades periféricas |
KR20180098222A (ko) * | 2015-10-02 | 2018-09-03 | 컴플렉사, 인코포레이티드 | 활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행 |
CN117843645A (zh) | 2018-05-25 | 2024-04-09 | 伊马拉公司 | 一种pde9抑制剂的一水合物和结晶形态 |
CN111229120B (zh) * | 2018-11-29 | 2022-01-07 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
CN111229117B (zh) * | 2018-11-29 | 2022-01-04 | 中国石油化工股份有限公司 | 含脂肪酸型表面活性剂的混合体系及其制备方法 |
FR3092968B1 (fr) * | 2019-02-22 | 2021-05-21 | Microphyt | Complement alimentaire |
CN110157792A (zh) * | 2019-04-22 | 2019-08-23 | 中山大学孙逸仙纪念医院 | 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用 |
WO2021242758A1 (en) * | 2020-05-26 | 2021-12-02 | Imara Inc. | Improved nitro-fatty acid oral dose regimens |
WO2023014748A1 (en) * | 2021-08-03 | 2023-02-09 | Imara Inc. | Nitrated fatty acids for the treatment of sickle cell disorders |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB587992A (en) | 1944-12-11 | 1947-05-12 | Charles William Scaife | Improvements in and relating to the production of organic nitrogen compounds |
US3578687A (en) | 1968-01-30 | 1971-05-11 | Texaco Inc | Process for producing 4-nitroalkanoic acids |
US3819561A (en) | 1970-10-23 | 1974-06-25 | Aerojet General Co | Wetting agents for non-aqueous dispersions |
JPS5313608B2 (es) | 1972-06-16 | 1978-05-11 | ||
JPS5318013B2 (es) | 1973-03-19 | 1978-06-13 | ||
US4599430A (en) | 1981-12-21 | 1986-07-08 | The Standard Oil Company | Nitrogenation of hydrocarbons, including the production of maleimide |
JPS62132804A (ja) | 1985-12-05 | 1987-06-16 | Aguro Kanesho Kk | 植物生長調節剤 |
US5412137A (en) | 1993-06-07 | 1995-05-02 | Sandoz Ltd. | Process for preparing phosphinyloxy propanaminium inner salt derivatives |
CA2202503C (en) | 1994-10-13 | 2008-07-15 | Antonio Ferrante | Modified polyunsaturated fatty acids |
US5919816A (en) | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
US5741211A (en) | 1995-10-26 | 1998-04-21 | Medtronic, Inc. | System and method for continuous monitoring of diabetes-related blood constituents |
GB9618420D0 (en) | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
WO1999022719A1 (fr) | 1997-10-30 | 1999-05-14 | Morishita Jintan Co., Ltd. | Preparation de capsule contenant un acide gras insature ou un derive de celui-ci, et procede de fabrication |
AU5565599A (en) | 1998-08-14 | 2000-03-06 | Dante J. Marciani | Chemically modified saponins and the use thereof as adjuvants |
IL145712A0 (en) | 1999-04-01 | 2002-07-25 | Esperion Therapeutics Inc | Ether compounds, compositions, and uses thereof |
WO2001006983A2 (en) | 1999-07-22 | 2001-02-01 | Incell Corporation, Llc | Fatty acids to minimize cancer therapy side effects |
SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
AUPQ291499A0 (en) | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
US6346231B1 (en) | 1999-10-06 | 2002-02-12 | Joar Opheim | Flavored gelatin capsule and method of manufacture |
US20010037598A1 (en) | 1999-12-14 | 2001-11-08 | Suppes Galen J. | Process for producing cetane improvers from triglycerides |
WO2001060778A2 (en) | 2000-02-16 | 2001-08-23 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
AR030416A1 (es) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA |
AR034120A1 (es) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico |
AR032318A1 (es) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
CA2412232C (en) | 2000-06-28 | 2010-03-30 | Zambon Group S.P.A. | Process for the preparation of nitroalkenes |
AR031129A1 (es) | 2000-09-15 | 2003-09-10 | Pharmacia Corp | Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa |
DE60223670T2 (de) | 2001-04-18 | 2008-03-06 | Prometic Biosciences Inc., Mont-Royal | Fettsäuren als Faktoren für das Überleben und die Aktivierung von Neutrophilen. |
US7105556B2 (en) | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
WO2002102364A1 (fr) | 2001-06-18 | 2002-12-27 | Yamada, Sachiko | Preparations medicamenteuses agonistes ppar$g(g) |
CN1571672A (zh) | 2001-08-17 | 2005-01-26 | 匹兹堡大学 | 给予雌二醇代谢物治疗或预防肥胖症、代谢综合征、糖尿病以及血管和肾脏疾病 |
GB0123961D0 (en) | 2001-10-05 | 2001-11-28 | Astrazeneca Ab | Process and intermediates |
US20030166716A1 (en) | 2001-11-06 | 2003-09-04 | Serhan Charles N. | Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases |
US7759395B2 (en) | 2002-08-12 | 2010-07-20 | The Brigham And Women's Hospital, Inc. | Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma |
CA2875522A1 (en) | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
AU2003272738B2 (en) | 2002-09-27 | 2010-04-01 | Martek Biosciences Corporation | Docosahexaenoic acid for improved glycemic control |
US7166575B2 (en) | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
WO2005016864A1 (en) | 2003-07-29 | 2005-02-24 | The Arizona Disease Control Research Commission | Conjugated nitro alkene anticancer agents based on isoprenoid metabolism |
US20050136103A1 (en) | 2003-09-17 | 2005-06-23 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
US7935365B2 (en) | 2003-10-22 | 2011-05-03 | Enzymotec, Ltd. | Glycerophospholipids for the improvement of cognitive functions |
WO2005073164A1 (en) | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
CA2563533C (en) | 2004-04-15 | 2013-10-01 | Shmuel A. Ben-Sasson | Compositions capable of facilitating penetration across a biological barrier |
US7776916B2 (en) * | 2004-04-28 | 2010-08-17 | The Uab Research Foundation | Nitrated lipids and methods of making and using thereof |
NZ553263A (en) | 2004-07-19 | 2010-06-25 | Biocon Ltd | Insulin-oligomer conjugates, formulations and uses thereof |
EP1772149A1 (en) | 2004-07-27 | 2007-04-11 | Kowa Company. Ltd. | Drug for prevention or treatment of diabetes |
EP1824809A4 (en) | 2004-11-19 | 2010-03-03 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN, MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
US20070032420A1 (en) | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
US9274129B2 (en) | 2006-05-31 | 2016-03-01 | Lpath, Inc. | Methods and reagents for detecting bioactive lipids |
US20090264483A1 (en) | 2006-07-14 | 2009-10-22 | Cedars-Sinai Medical Center | METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
CN101528218A (zh) | 2006-07-19 | 2009-09-09 | 雷索维克斯药品公司 | 治疗粘膜炎的组合物和方法 |
EP2120920A4 (en) | 2007-02-20 | 2011-06-15 | Martek Biosciences Corp | OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE |
DK2180787T3 (da) | 2007-08-01 | 2014-02-03 | Univ Pittsburgh | Nitrooliesyremodulering af type ii-diabetes |
AU2008301895A1 (en) | 2007-09-14 | 2009-03-26 | Resolvyx Pharmaceuticals, Inc. | Oxylipin compounds for treating autoimmune diseases |
EP2271929B1 (en) | 2008-04-18 | 2015-11-25 | The University of Utah Research Foundation | Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions |
WO2009134383A2 (en) | 2008-05-01 | 2009-11-05 | Complexa Inc. | Vinyl substituted fatty acids |
WO2009149496A1 (en) | 2008-06-10 | 2009-12-17 | Central Northern Adelaide Health Service | Treatment of diabetes and complications thereof and related disorders |
US20140024713A1 (en) * | 2008-06-19 | 2014-01-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
WO2009155439A2 (en) | 2008-06-19 | 2009-12-23 | University Of Utah Research Foundation | Use of nitrated lipids for treatment of side effects of toxic medical therapies |
WO2010012777A1 (en) | 2008-07-29 | 2010-02-04 | Nerviano Medical Sciences S.R.L. | THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
AU2009334476B2 (en) * | 2008-12-31 | 2013-08-29 | Nitromega Corp. | Nutraceuticals containing nitro fatty acids |
US8937194B2 (en) * | 2008-12-31 | 2015-01-20 | Nitromega Corp. | Topical compositions containing nitro fatty acids |
US20100286272A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications |
US20100286271A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Nitro-alkyl Compound Compositions |
US20100286257A1 (en) | 2009-05-08 | 2010-11-11 | Perricone Nicholas V | Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging |
JP2013500275A (ja) | 2009-07-29 | 2013-01-07 | フェノメノーム ディスカバリーズ インク | ヒドロキシ脂肪酸化合物並びに疾患治療及び診断のためのその使用 |
EP2459189A4 (en) | 2009-07-31 | 2013-01-16 | Univ Pittsburgh | FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES |
EP2483233A4 (en) | 2009-10-02 | 2013-08-14 | Complexa Inc | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS |
CN102822152A (zh) | 2009-11-09 | 2012-12-12 | 诺瓦德克斯制药股份有限公司 | 新颖的1,3-噁唑烷化合物及其作为肾素抑制剂的用途 |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
WO2011113507A2 (en) * | 2010-03-15 | 2011-09-22 | Ulrich Dietz | Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
JP2013526865A (ja) | 2010-05-13 | 2013-06-27 | ニトロメガ コーポレーション | ニトロ脂肪酸、神経保護および/または認識減退の抑制 |
JP2013534930A (ja) | 2010-06-28 | 2013-09-09 | コンプレクサ,インコーポレイテッド | 糖尿病を治療するための多成分調剤 |
EP2744491B1 (en) * | 2011-08-19 | 2020-07-29 | The University of Utah Research Foundation | Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system |
US9271952B2 (en) | 2011-10-11 | 2016-03-01 | Complexa, Inc. | Compositions and methods for treating nephropathy |
DE102012008730A1 (de) | 2011-12-02 | 2013-06-06 | Dr. Budz GmbH | Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung |
CA2863765A1 (en) | 2012-02-03 | 2013-08-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Fatty acids as anti-inflammatory agents |
US20140271844A1 (en) * | 2013-03-15 | 2014-09-18 | Nitromega Corp. | Compositions containing nitro fatty acids |
CN105339006A (zh) | 2013-05-10 | 2016-02-17 | 尼特罗米加公司 | 含有脂肪酸和亚硝酸盐的营养或膳食补充剂 |
US20150051283A1 (en) | 2013-06-14 | 2015-02-19 | Complexa, Inc. | Composition and method for inhibition of pkng from mycobacterium tuberculosis |
WO2015073527A1 (en) | 2013-11-12 | 2015-05-21 | Complexa, Inc. | Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions |
WO2016161285A1 (en) * | 2015-04-02 | 2016-10-06 | Aobiome Llc | Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria |
KR20180098222A (ko) * | 2015-10-02 | 2018-09-03 | 컴플렉사, 인코포레이티드 | 활성화된 지방산의 치료학적 유효량을 이용한 질환의 예방, 치료 및 역행 |
-
2016
- 2016-10-03 KR KR1020187012337A patent/KR20180098222A/ko not_active Application Discontinuation
- 2016-10-03 WO PCT/US2016/055206 patent/WO2017059451A1/en active Application Filing
- 2016-10-03 US US15/283,887 patent/US10537541B2/en not_active Expired - Fee Related
- 2016-10-03 AU AU2016331314A patent/AU2016331314A1/en not_active Abandoned
- 2016-10-03 JP JP2018536704A patent/JP2018529779A/ja not_active Withdrawn
- 2016-10-03 SG SG10201913953UA patent/SG10201913953UA/en unknown
- 2016-10-03 CA CA3000842A patent/CA3000842A1/en not_active Abandoned
- 2016-10-03 EA EA201890859A patent/EA201890859A1/ru unknown
- 2016-10-03 EP EP16852846.1A patent/EP3355879A4/en not_active Withdrawn
- 2016-10-03 CN CN201680070797.XA patent/CN108430466A/zh active Pending
- 2016-10-03 IL IL258476A patent/IL258476B2/en unknown
- 2016-10-03 CR CR20180246A patent/CR20180246A/es unknown
- 2016-10-03 CN CN202110744035.6A patent/CN113440506A/zh active Pending
- 2016-10-03 MX MX2018004043A patent/MX2018004043A/es unknown
- 2016-10-03 BR BR112018006687A patent/BR112018006687A2/pt not_active Application Discontinuation
- 2016-10-03 IL IL297844A patent/IL297844A/en unknown
-
2018
- 2018-03-29 CL CL2018000835A patent/CL2018000835A1/es unknown
- 2018-04-27 CO CONC2018/0004576A patent/CO2018004576A2/es unknown
-
2019
- 2019-01-29 HK HK19101519.9A patent/HK1259031A1/zh unknown
- 2019-10-18 US US16/657,028 patent/US20200046669A1/en not_active Abandoned
-
2021
- 2021-03-19 US US17/207,380 patent/US20220000824A1/en not_active Abandoned
- 2021-07-14 AU AU2021205027A patent/AU2021205027A1/en not_active Abandoned
- 2021-08-27 JP JP2021139287A patent/JP2021183640A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL297844A (en) | 2023-01-01 |
EP3355879A1 (en) | 2018-08-08 |
AU2016331314A1 (en) | 2018-05-17 |
AU2021205027A1 (en) | 2021-08-12 |
WO2017059451A1 (en) | 2017-04-06 |
EA201890859A1 (ru) | 2018-11-30 |
JP2018529779A (ja) | 2018-10-11 |
CN108430466A (zh) | 2018-08-21 |
US10537541B2 (en) | 2020-01-21 |
US20200046669A1 (en) | 2020-02-13 |
CA3000842A1 (en) | 2017-04-06 |
IL258476B2 (en) | 2023-04-01 |
CL2018000835A1 (es) | 2018-09-14 |
HK1259031A1 (zh) | 2019-11-22 |
JP2021183640A (ja) | 2021-12-02 |
BR112018006687A2 (pt) | 2018-10-09 |
US20170095437A1 (en) | 2017-04-06 |
KR20180098222A (ko) | 2018-09-03 |
CR20180246A (es) | 2018-11-22 |
IL258476A (en) | 2018-06-28 |
SG10201913953UA (en) | 2020-03-30 |
IL258476B (en) | 2022-12-01 |
EP3355879A4 (en) | 2019-05-22 |
US20220000824A1 (en) | 2022-01-06 |
CN113440506A (zh) | 2021-09-28 |
MX2018004043A (es) | 2018-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018004576A2 (es) | Composición farmacéutica que comprende ácidos grasos activados | |
SV2017005555A (es) | Composiciones de acido obeticolico y metodos de uso | |
CL2017002606A1 (es) | Inhibidor de bromodominio | |
BR112018010650A8 (pt) | pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal | |
CO2017012267A2 (es) | Compuestos de naftiridina como inhibidores de la quinasa jak | |
CL2017000780A1 (es) | Composiciones y métodos para silenciar la expresión del virus gen de la hepatitis b | |
ECSP19043710A (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
CL2017002650A1 (es) | Compuestos novedosos | |
DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
DOP2012000257A (es) | Derivados del acido 1-amino-2-ciclopropiletilboronico | |
NI201700056A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer | |
EA201792028A1 (ru) | Альфа-цинамидные соединения и композиции как ингибиторы hdac8 | |
BR112014028042A2 (pt) | inibidores de nampt | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
BR112019021867A2 (pt) | Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil | |
CL2017002299A1 (es) | Combinaciones de dosis fija y formulaciones comprendiendo etc-1002 y ezetimiba y métodos para tratar o reducir el riesgo de enfermedades cardiovasculares | |
CL2018003187A1 (es) | Ésteres de oxaborol y sus usos. | |
DOP2016000120A (es) | Nuevos inhibidores de dgat2 | |
EA201891468A1 (ru) | Композиции и способы для снижения экспрессии tau | |
CO2017000950A2 (es) | Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos | |
EP3318261A4 (en) | Use of zoledronic acid to prepare drug treating fatty liver disease | |
DK3082795T3 (da) | Sammensætninger af omega 3 fedtsyrer til behandling af sygdomme, der involverer skader på nervesystemet | |
BR112019025420A2 (pt) | Compostos policíclicos e usos destes |